Cooper Companies, Inc. (COO)

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Ticker
COO
Exchange
Nasdaq
Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$11.55B
52-week range
$51.01 - $89.83

Valuation

Share price
$60.75 (close of Nov 18, 2026)
P/E (TTM)
20.66x
Price to book
1.39x
Price to free cash flow
17.03x
Enterprise value
$13.94B
Book value per share
$43.81

Price performance

PeriodChange
1 day+0.05%
5 days-3.46%
1 month+4.85%
3 months-19.81%
6 months-0.31%
Year to date-25.88%
1 year-15.86%
3 years-27.92%
5 years-39.98%
10 years+41.28%
All time+671.43%

Short interest

As of
Oct 30, 2026
Short % of float
6.09%
Shares short
10.11M
Days to cover
3.36
Change since prior report
+11.28%
Source
FINRA consolidated short interest

Members of Congress who disclosed COO trades

Gilbert Ray Cisneros · Alan Armstrong · Robert Bresnahan

Super investors holding COO

Glenn Greenberg (Brave Warrior Advisors, LLC) · Ken Griffin (Citadel) · Bill Nygren (Harris Associates LP) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on equity
4.55%
Return on invested capital
4.57%
Return on assets
3.02%
Return on capital employed
6.05%
Gross margin
65.54%
Net margin
9.16%
EBITDA margin
25.91%
Revenue growth
5.06%
Net income growth
-4.44%
Free cash flow growth
50.54%

Cash flow and balance sheet

Free cash flow yield (TTM)
5.87%
Current ratio
1.22x
Net debt to EBITDA
2.55x

Latest reported year

Period end
Oct 31, 2025
Fiscal year
2025
Revenue
$4.09B
Cost of revenue
$1.41B
Gross profit
$2.68B
EBITDA
$1.06B
Net income
$374.90M
Earnings per share
$1.88
Research and development
$172.20M
Interest expense
$100.00M
Shares outstanding
199.10M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-10-31$4.09B$2.68B$374.90M$1.88
2024-10-31$3.90B$2.60B$392.30M$1.97
2023-10-31$3.59B$2.36B$294.20M$1.49
2022-10-31$3.31B$2.14B$385.80M$1.95
2021-10-31$2.92B$1.96B$2.94B$14.95
2020-10-31$2.43B$1.53B$238.40M$1.21
2019-10-31$2.65B$1.76B$466.70M$2.36
2018-10-31$2.53B$1.63B$139.90M$0.71
2017-10-31$2.14B$1.37B$372.90M$1.91
2016-10-31$1.97B$1.17B$273.90M$1.41

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-10-3165.54%9.16%4.55%4.57%
2024-10-3166.64%10.07%4.85%4.83%
2023-10-3165.62%8.19%3.90%4.09%
2022-10-3164.67%11.66%5.38%4.21%
2021-10-3166.92%100.76%42.42%5.82%
2020-10-3163.14%9.81%6.23%4.82%
2019-10-3166.21%17.59%12.86%9.83%
2018-10-3164.45%5.52%4.23%3.96%
2017-10-3163.85%17.43%11.74%9.38%
2016-10-3159.65%13.93%10.16%7.16%

Cash and debt by year

Period endCashDebt
2025-10-31$110.60M$2.46B
2024-10-31$107.60M$2.55B
2023-10-31$120.80M$2.52B
2022-10-31$138.20M$2.35B
2021-10-31$95.90M$1.40B
2020-10-31$115.90M$1.38B
2019-10-31$89.00M$1.26B
2018-10-31$77.70M$1.99B
2017-10-31$88.80M$1.15B
2016-10-31$100.80M$1.11B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-10-31$433.70M$70.50M
2024-10-31$288.10M$75.10M
2023-10-31$215.00M$62.10M
2022-10-31$450.40M$54.20M
2021-10-31$524.20M$43.80M
2020-10-31$176.20M$37.60M
2019-10-31$421.10M$35.10M
2018-10-31$475.30M$43.20M
2017-10-31$466.40M$37.20M
2016-10-31$357.00M$29.90M

Dividend history

Most recent payment
Jul 26, 2023
Payment dateDividend per share
2023-07-26$0.03
2023-01-20$0.03
2022-07-26$0.03
2022-01-20$0.03
2021-07-26$0.03
2021-01-21$0.03
2020-07-22$0.03
2020-01-22$0.03

Investor relations

Next earnings report

Next confirmed report
Dec 3, 2026
Consensus EPS estimate
$1.07

Past earnings dates

ReportedFiscal periodEPS estimate
2026-09-09Jul 2026$1.11
2026-06-04Apr 2026$1.10
2026-03-05Jan 2026$1.03
2025-12-04Oct 2025$1.11
2025-08-27Jul 2025$1.07
2025-05-29Apr 2025$0.93
2025-03-06Jan 2025$0.92
2024-12-05Oct 2024$1.00

Filings and sources

Company website
coopercos.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Align Technology Inc (ALGN) · Avantor, Inc. (AVTR) · Repligen Corp (RGEN) · Baxter International Inc (BAX) · Teleflex Inc (TFX) · Solventum Corp (SOLV) · West Pharmaceutical Services Inc (WST) · Alcon Inc (ALC)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades